CS
CSTL icon

Credit Suisse’s Castle Biosciences CSTL Stock Holding History

Credit Suisse’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$793K Buy
35,809
+1,759
+5% +$38.3K ﹤0.01% 2401
2023
Q4 		$735K Buy
34,050
+4,598
+16% +$80.9K ﹤0.01% 2535
2023
Q3 		$497K Sell
29,452
-1,462
-5% -$25.6K ﹤0.01% 2695
2023
Q2 		$424K Buy
30,914
+3,124
+11% +$63.3K ﹤0.01% 2870
2023
Q1 		$631K Buy
27,790
+4,618
+20% +$113K ﹤0.01% 2611
2022
Q4 		$545K Buy
23,172
+7,233
+45% +$168K ﹤0.01% 2730
2022
Q3 		$416K Buy
15,939
+276
+2% +$7.74K ﹤0.01% 2897
2022
Q2 		$345K Buy
15,663
+799
+5% +$18.6K ﹤0.01% 3080
2022
Q1 		$667K Buy
14,864
+1,706
+13% +$70.5K ﹤0.01% 2810
2021
Q4 		$564K Buy
13,158
+365
+3% +$19.1K ﹤0.01% 3731
2021
Q3 		$851K Buy
12,793
+798
+7% +$56.2K ﹤0.01% 3465
2021
Q2 		$879K Sell
11,995
-589
-5% -$38.9K ﹤0.01% 3486
2021
Q1 		$862K Buy
12,584
+314
+3% +$23.6K ﹤0.01% 3419
2020
Q4 		$823K Buy
12,270
+2,956
+32% +$160K ﹤0.01% 3469
2020
Q3 		$479K Buy
+9,314
New +$414K ﹤0.01% 3424

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Credit Suisse's CSTL Position: Q1 2024 in Review

Credit Suisse increased its Castle Biosciences (CSTL) stake by 5.2% in Q1 2024, buying an estimated $38.3K and bringing the position to 35,809 shares worth $793K. The position accounts for ﹤0.01% of the portfolio, ranked #2401.

Credit Suisse first reported a position in CSTL in Q3 2020 and has held it in 15 quarters since. The position peaked at $879K in Q2 2021. 151 funds tracked by Wall St. Rank hold CSTL as of Q1 2024.

  • Credit Suisse held 35,809 shares of Castle Biosciences worth $793K as of Q1 2024.
  • Credit Suisse bought 1,759 Castle Biosciences shares in Q1 2024, an estimated $38.3K.
  • Castle Biosciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2401 holding.
  • Credit Suisse first reported a position in Castle Biosciences in Q3 2020 and has held it in 15 quarters since.
  • Credit Suisse's Castle Biosciences position peaked at $879K in Q2 2021.
  • 151 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.